Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05735483 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05735483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05735483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
March 9, 2023
Completion date
April 30, 2029
Enrollment
333 (estimated)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, eczema